PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic LDL receptor (LDLR) recycling. Inhibiting PCSK9 results in improved LDLR recycling, increased LDLR availability on hepatocyt...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Vasc Health Risk Manag
Main Authors: Blom, Dirk J, Dent, Ricardo, Castro, Rita C, Toth, Peter P
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2016
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868869/
https://ncbi.nlm.nih.gov/pubmed/27274264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S102564
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki